CXI Healthcare Technology Group Crecimiento futuro

Future controles de criterios 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for CXI Healthcare Technology Group.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Personal Products	11.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Insufficient Growth At CXI Healthcare Technology Group Limited (KOSDAQ:900120) Hampers Share Price

Sep 30

CXI Healthcare Technology Group (KOSDAQ:900120) Is Experiencing Growth In Returns On Capital

Aug 05

Lacklustre Performance Is Driving CXI Healthcare Technology Group Limited's (KOSDAQ:900120) Low P/S

May 30

How Much Did CKH Food & Health's(KOSDAQ:900120) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 02

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como CXI Healthcare Technology Group no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

KOSDAQ:A900120 - Estimaciones futuras de los analistas y datos financieros pasados (KRW Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	69,420	29,349	43,666	43,666	N/A
3/31/2024	67,194	21,013	42,610	42,610	N/A
12/31/2023	68,673	17,446	41,272	41,272	N/A
9/30/2023	69,715	12,117	35,049	35,049	N/A
6/30/2023	71,617	7,528	31,597	31,597	N/A
3/31/2023	79,065	1,294	33,115	33,121	N/A
12/31/2022	87,718	3,198	34,513	34,519	N/A
9/30/2022	98,052	9,532	37,885	37,891	N/A
6/30/2022	101,376	5,981	35,979	35,984	N/A
3/31/2022	103,312	6,182	31,884	34,802	N/A
12/31/2021	105,354	4,302	-78,688	33,577	N/A
9/30/2021	108,284	2,762	-131,371	24,526	N/A
6/30/2021	104,593	5,098	-196,165	8,723	N/A
3/31/2021	81,035	-55,823	-279,044	-11,374	N/A
12/31/2020	64,812	-70,201	-182,182	-23,860	N/A
9/30/2020	63,264	-83,142	-152,506	-37,816	N/A
6/30/2020	63,406	-98,437	-110,022	-44,322	N/A
3/31/2020	82,358	-61,945	-41,425	-41,418	N/A
12/31/2019	106,374	-64,559	-51,724	-51,707	N/A
9/30/2019	117,046	-67,216	-50,748	-50,706	N/A
6/30/2019	129,309	-70,621	-58,101	-58,060	N/A
3/31/2019	147,921	-64,977	-64,012	-63,977	N/A
12/31/2018	149,568	-66,308	-60,023	-59,997	N/A
9/30/2018	148,347	-72,578	-64,361	-64,361	N/A
6/30/2018	145,264	-73,933	-57,435	-57,435	N/A
3/31/2018	120,456	-70,977	N/A	-34,471	N/A
12/31/2017	120,228	-49,884	N/A	-13,879	N/A
9/30/2017	125,336	-24,445	N/A	14,958	N/A
6/30/2017	146,319	786	N/A	54,284	N/A
3/31/2017	190,109	18,964	N/A	48,143	N/A
12/31/2016	228,969	29,945	N/A	65,841	N/A
9/30/2016	269,185	42,624	N/A	75,067	N/A
6/30/2016	297,600	52,396	N/A	59,172	N/A
3/31/2016	311,164	60,931	N/A	88,396	N/A
12/31/2015	318,262	66,823	N/A	86,723	N/A
9/30/2015	321,330	71,473	N/A	89,229	N/A
6/30/2015	317,895	73,452	N/A	95,513	N/A
3/31/2015	312,412	69,309	N/A	77,966	N/A
12/31/2014	303,794	68,530	N/A	74,266	N/A
9/30/2014	291,664	65,401	N/A	75,546	N/A
6/30/2014	286,376	63,604	N/A	77,930	N/A
3/31/2014	285,469	66,365	N/A	87,930	N/A
12/31/2013	279,352	62,672	N/A	83,793	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Insufficient data to determine if A900120's forecast earnings growth is above the savings rate (2.6%).

Beneficios vs. Mercado: Insufficient data to determine if A900120's earnings are forecast to grow faster than the KR market

Beneficios de alto crecimiento: Insufficient data to determine if A900120's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: Insufficient data to determine if A900120's revenue is forecast to grow faster than the KR market.

Ingresos de alto crecimiento: Insufficient data to determine if A900120's revenue is forecast to grow faster than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if A900120's Return on Equity is forecast to be high in 3 years time

CXI Healthcare Technology Group Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

CXI Healthcare Technology Group Limited announced that it has received KRW 999.999999 million in funding from Beauty Skin Corp.

CXI Healthcare Technology Group Limited, Annual General Meeting, Oct 24, 2024

CXI Healthcare Technology Group Limited, Annual General Meeting, Oct 24, 2024

Insufficient Growth At CXI Healthcare Technology Group Limited (KOSDAQ:900120) Hampers Share Price

CXI Healthcare Technology Group (KOSDAQ:900120) Is Experiencing Growth In Returns On Capital

Lacklustre Performance Is Driving CXI Healthcare Technology Group Limited's (KOSDAQ:900120) Low P/S

Investor sentiment improves as stock rises 28%

New major risk - Shareholder dilution

First quarter 2024 earnings released: EPS: ₩34.00 (vs ₩16.00 in 1Q 2023)

CKH Food & Health Limited announced that it has received KRW 7.432995165 billion in funding

New minor risk - Share price stability

Investor sentiment improves as stock rises 35%

Investor sentiment deteriorates as stock falls 16%

New major risk - Shareholder dilution

Third quarter 2023 earnings released: ₩6.00 loss per share (vs ₩7.00 profit in 3Q 2022)

Second quarter 2023 earnings released: ₩41.00 loss per share (vs ₩2.00 loss in 2Q 2022)

CKH Food & Health Limited has completed a Follow-on Equity Offering in the amount of KRW 999.99999 million.

First quarter 2023 earnings released: EPS: ₩16.00 (vs ₩11.00 loss in 1Q 2022)

No independent directors

Investor sentiment improved over the past week

CKH Food & Health Limited announced that it has received KRW 10.911791808 billion in funding from Rui Xing International Holdings Limited

CKH Food & Health Limited announced that it expects to receive KRW 10.911791808 billion in funding from Rui Xing International Holdings Limited, and other investors

Third quarter 2022 earnings released: EPS: ₩7.00 (vs ₩9.00 loss in 3Q 2021)

No independent directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

CKH Food & Health Limited has completed a Follow-on Equity Offering in the amount of KRW 999.99981 million.

Third quarter 2021 earnings released: ₩9.00 loss per share (vs ₩139 loss in 3Q 2020)

CKH Food & Health Limited announced that it has received KRW 2.270259148 billion in funding

CKH Food & Health Limited announced that it expects to receive KRW 2.270259148 billion in funding

CKH Food & Health Limited announced that it has received KRW 679.08 million in funding

CKH Food & Health Limited announced that it expects to receive KRW 679.08 million in funding

Second quarter 2021 earnings released: ₩17.00 loss per share (vs ₩133 loss in 2Q 2020)

New 90-day low: ₩405

First quarter 2021 earnings released: EPS ₩10.00

How Much Did CKH Food & Health's(KOSDAQ:900120) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: ₩354

New 90-day high: ₩295

New 90-day high: ₩274

New 90-day low - ₩212

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento